Chordia Therapeutics (190A.T) plunged 22.16% to JPY 130.00 at the JPX close on 03 Mar 2026, marking one of the top losers on the session. The drop followed a surge in intraday volume to 6412000.00 shares versus an average of 1738356.00, signalling heavy sell pressure. This move pushed the share price below the 200-day average of 154.44 JPY and raised fresh questions about valuation and near-term catalysts for the 190A.T stock.

Intraday price action and liquidity: 190A.T stock

Chordia opened at 145.00 JPY and traded between 128.00 and 145.00 JPY before settling at 130.00 JPY. Volume jumped to 6412000.00, a relVolume of 7.93, far above the average 1738356.00. The high liquidity amplified the slide and made short-term trading riskier for 190A.T stock.

Fundamentals snapshot: 190A.T stock financials

The company is in Healthcare, Medical – Pharmaceuticals, headquartered in Japan and listed on JPX. Key metrics show EPS -26.04, PE -5.88, cash per share 33.54 JPY, and book value per share 32.95 JPY. Market cap stands at 10737555300.00 JPY with 70180100.00 shares outstanding. These metrics point to negative profitability and a high price-to-book ratio of 4.64, underlining valuation risks for 190A.T stock.

Technical signals: 190A.T stock momentum and indicators

Momentum indicators showed mixed signals before the sell-off: RSI at 65.63 and MACD histogram 3.63 suggested recent strength, but the large volume spike and ATR of 10.49 indicate higher near-term volatility. Bollinger band upper/lower bounds at 148.53 and 96.17 JPY highlight a wide trading range. Traders should note the 50-day average 117.26 JPY and 200-day average 154.44 JPY when sizing positions in 190A.T stock.

Meyka AI rating and model forecast: 190A.T stock

Meyka AI rates 190A.T with a score out of 100: 65.55 (Grade B) and suggests HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of 126.08 JPY versus the current 130.00 JPY, implying an implied downside of -3.08%. Forecasts are model-based projections and not guarantees. For further company detail see the official site Chordia Therapeutics and our internal profile Chordia on Meyka.

Risks and catalysts affecting 190A.T stock

Primary risks include clinical trial setbacks, R&D expense pressure, and negative EPS trends; current EPS is -26.04. Catalysts that could reverse the decline include positive Proof of Concept results, licensing deals, or clearer cash runway updates. Given a current cash-per-share buffer of 33.54 JPY, liquidity risk is present but not immediate for 190A.T stock.

Trading outlook and price targets: 190A.T stock

Short-term technical support sits near the year low at 98.00 JPY and the 50-day average at 117.26 JPY. Meyka AI model-based near-term median is 126.08 JPY. We outline a scenario set: conservative price target 98.00 JPY (bear), model median 126.08 JPY, and a bull target 170.00 JPY tied to successful clinical news. Position sizing should reflect high volatility and sector norms for Medical – Pharmaceuticals.

Final Thoughts

Chordia Therapeutics (190A.T stock) finished the JPX session on 03 Mar 2026 down 22.16% at JPY 130.00, driven by a volume surge to 6412000.00 and a break below the 200-day average. Fundamentals show negative earnings with EPS -26.04 and a high PB of 4.64, consistent with elevated valuation risk for this healthcare small-cap. Meyka AI rates 190A.T with a 65.55/100 score (Grade B, HOLD) and its model projects JPY 126.08, implying -3.08% downside from the close. Traders should watch near-term catalysts — POC trial updates or licensing progress — and respect technical support at 117.26 and 98.00 JPY. This event qualifies 190A.T stock as a top loser today, but any material clinical news could quickly change the outlook. Meyka AI, our AI-powered market analysis platform, will track updates and re-run forecasts after formal company announcements. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.